Review





Similar Products

ahr inhibitor ch223191  (MedChemExpress)
98
MedChemExpress ahr inhibitor ch223191
Ahr Inhibitor Ch223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch223191/CH-223191/pmc13449032-212-1-10
Average 98 stars, based on 1 article reviews
ahr inhibitor ch223191 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
ch223191  (MedChemExpress)
98
MedChemExpress ch223191
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Ch223191, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch223191/CH-223191/pmc13453838-60-25-27
Average 98 stars, based on 1 article reviews
ch223191 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
ch223191  (Selleck Chemicals)
94
Selleck Chemicals ch223191
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Ch223191, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch223191/CH-223191/pm41872128-77-11-12
Average 94 stars, based on 1 article reviews
ch223191 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
ahr inhibitor ch223191 ch  (MedChemExpress)
98
MedChemExpress ahr inhibitor ch223191 ch
Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and <t>CH223191</t> treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.
Ahr Inhibitor Ch223191 Ch, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ch223191/CH-223191/pm41731543-90-45-51
Average 98 stars, based on 1 article reviews
ahr inhibitor ch223191 ch - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier

Image Search Results


Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Journal of Advanced Research

Article Title: The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma

doi: 10.1016/j.jare.2025.10.079

Figure Lengend Snippet: Combination AhR inhibitor with anti-PD-1 antibody, gemcitabine and PRMT5 inhibitor improved the therapeutic effect of tumor. (A)-(G) Anti-PD1 antibody and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (A): Schematic diagram of mouse modeling and treatment. (B): Tumor images. (C): Tumor weights. (D): Overall survival of the mice. (E): H&E staining of subcutaneous tumors. IHC staining of CD4 + (F) and CD8 + (G) T cells in the tumors. (H)-(N) GEM and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (H): Schematic diagram of mouse modeling and treatment. (I): Tumor images. (J): Tumor weight. (K): Overall survival of the mice. (L): H&E staining of subcutaneous tumors. IHC staining of CD4 + (M) and CD8 + (N) T cells in the tumors. (O)-(U) GSK3326595 and CH223191 treatment in Pan02-induced subcutaneous tumor model in C57BL/6 mice. (O): Schematic diagram of mouse modeling and treatment. (P): Tumor images. (Q): Tumor weights. (R): Overall survival of the mice. (S): H&E staining of subcutaneous tumors. IHC staining of CD4 + (T) and CD8 + (U) T cells in the tumors. The data are presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: 2 μM Benzo[a]pyrene (B1760; Merck) and 100 μM kynurenine (HY-104026; MedChemExpress) were used as AhR agonists to activate the AhR signaling pathway, while 20 μM CH223191 (HY-12684; MedChemExpress) and 20 μM resveratrol (HY-16561; MedChemExpress) were employed as AhR antagonists to inhibit the pathway.

Techniques: Staining, Immunohistochemistry